Detailed Information on Publication Record
2020
The association of lorg-term outcome and biological sex in patients with acute heart failure from different geographic regions
MOTIEJUNAITE, J., E. AKIYAMA, A. COHEN-SOLAL, A. P. MAGGIONI, C. MUELLER et. al.Basic information
Original name
The association of lorg-term outcome and biological sex in patients with acute heart failure from different geographic regions
Authors
MOTIEJUNAITE, J. (440 Lithuania), E. AKIYAMA (392 Japan), A. COHEN-SOLAL (250 France), A. P. MAGGIONI (380 Italy), C. MUELLER (756 Switzerland), D. J. CHOI (178 Congo), A. KAVOLIUNIENE (440 Lithuania), J. CELUTKIENE (440 Lithuania), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), J. LASSUS (246 Finland), K. KAJIMOTO (392 Japan), N. SATO (392 Japan), O. MIRO (724 Spain), W. F. PEACOCK (840 United States of America), Y. MATSUE (392 Japan), A. A. VOORS (528 Netherlands), C. S. P. LAM (702 Singapore), J. A. EZEKOWITZ (124 Canada), A. AHMED (840 United States of America), G. C. FONAROW (840 United States of America), E. GAYAT (250 France), V. REGITZ-ZAGROSEK (276 Germany) and A. MEBAZAA (250 France, guarantor)
Edition
European heart journal, Oxford, Oxford University Press, 2020, 0195-668X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 29.983
RIV identification code
RIV/00216224:14110/20:00116018
Organization unit
Faculty of Medicine
UT WoS
000522664500012
Keywords in English
Acute heart failure; Gender; Biological sex; Mortality; Prognosis
Tags
International impact, Reviewed
Změněno: 12/5/2021 13:15, Mgr. Tereza Miškechová
Abstract
V originále
Aims Recent data from national registries suggest that acute heart failure (AHF) outcomes might vary in men and women, however, it is not known whether this observation is universal. The aim of this study was to evaluate the association of biological sex and 1-year all-cause mortality in patients with AHF in various regions of the world. Methods and Results We analysed several AHF cohorts including GREAT registry (22 523 patients, mostly from Europe and Asia) and OPTIMIZE-HF (26 376 patients from the USA). Clinical characteristics and medication use at discharge were collected. Hazard ratios (HRs) for 1-year mortality according to biological sex were calculated using a Cox proportional hazards regression model with adjustment for baseline characteristics (e.g. age, comorbidities, clinical and laboratory parameters at admission, Left ventricular ejection fraction). In the GREAT registry, women had a Lower risk of death in the year following AHF [HR 0.86 (0.79-0.94), P< 0.001 after adjustment]. This was mostly driven by northeast Asia [n=9135, HR 0.76 (0.67-0.87), P< 0.001], while no significant differences were seen in other countries. In the OPTIMIZE-HF registry, women also had a tower risk of 1-year death [HR 0.93 (0.89-0.97), P < 0.001]. In the GREAT registry, women were less often prescribed with a combination of angiotensin-converting enzyme inhibitors and beta-Mockers at discharge (50% vs. 57%, P = 0.001). Conclusion Globally women with AHF have a lower 1-year mortality and less evidenced-based treatment than men. Differences among countries need further investigation. Our findings merit consideration when designing future global clinical trials in AHF.